Circulating tumor DNA: Solid data from liquid biopsies

Journal of Thoracic and Cardiovascular Surgery

Volumn 154, Issue 3, 2017, Pages 1132-1133

  Schrump, David S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG;

ACCURACY; ADVANCED CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; EARLY CANCER; EDITORIAL; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LIQUID BIOPSY; LUNG BIOPSY; LUNG CANCER; LUNG RESECTION; MEDICAL ONCOLOGIST; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SMOKING; THORACIC SURGEON; TUMOR BIOPSY; TUMOR GENE; LUNG TUMOR; MUTATION; NON SMALL CELL LUNG CANCER; TUMOR EMBOLISM;

CARCINOMA, NON-SMALL-CELL LUNG; CIRCULATING TUMOR DNA; HUMANS; LIQUID BIOPSY; LUNG NEOPLASMS; MUTATION; NEOPLASTIC CELLS, CIRCULATING;

EID: 85020758607     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2017.05.059     Document Type: Editorial

References (11)

1. Mandel, P., Metais, P., Les acides nucleiques du plasma sanguin chez l'homme. [in French] C R Seances Soc Biol Fil 142 (1948), 241–243.
2. Wan, J.C., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J.D., Caldas, C., et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17 (2017), 223–238.
3. Yang, M., Topaloglu, U., Petty, W.J., Pagni, M., Foley, K.L., Grant, S.C., et al. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. J Hematol Oncol, 10, 2017, 100.
4. Yeung, K.T., More, S., Woodward, B., Velculescu, V., Husain, H., Circulating tumor DNA for mutation detection and identification of mechanisms of resistance in non-small cell lung cancer. Mol Diagn Ther, March 24, 2017 [Epub ahead of print].
5. Cabel, L., Riva, F., Servois, V., Livartowski, A., Daniel, C., Rampanou, A., et al. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol, April 29, 2017 [Epub ahead of print].
6. U.S. Food and Drug Administration. FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504488.htm. Accessed May 10, 2017.
7. Chen, K., Zhang, J., Guan, T., Yang, F., Lou, F., Chen, W., et al. Comparison of plasma to tissue DNA mutations in surgical non–small cell lung cancer patients. J Thorac Cardiovasc Surg 154 (2017), 1123–1131.e2.
8. Guo, N., Lou, F., Ma, Y., Li, J., Yang, B., Chen, W., et al. Circulating tumor DNA detection in lung cancer patients before and after surgery. Sci Rep, 6, 2016, 33519.
9. Lu, Y., Li, S., Zhu, S., Gong, Y., Shi, J., Xu, L., Methylated DNA/RNA in body fluids as biomarkers for lung cancer. Biol Proced Online, 19, 2017, 2.
10. Lissa, D., Robles, A.I., Methylation analyses in liquid biopsy. Transl Lung Cancer Res 5 (2016), 492–504.
11. Zhang, Y.A., Ma, X., Sathe, A., Fujimoto, J., Wistuba, I.I., Lam, S., et al. Validation of SCT methylation as a hallmark biomarker for lung cancers. J Thorac Oncol 11 (2016), 346–360.